Fairmount Funds Management LLC bought a new position in shares of Inhibikase Therapeutics, Inc. (NYSE:IKT - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 6,125,000 shares of the company's stock, valued at approximately $19,906,000. Inhibikase Therapeutics accounts for approximately 2.0% of Fairmount Funds Management LLC's portfolio, making the stock its 16th biggest holding. Fairmount Funds Management LLC owned approximately 8.83% of Inhibikase Therapeutics as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently made changes to their positions in IKT. Blair William & Co. IL boosted its stake in shares of Inhibikase Therapeutics by 7.0% during the 4th quarter. Blair William & Co. IL now owns 134,953 shares of the company's stock worth $439,000 after acquiring an additional 8,833 shares during the period. Geode Capital Management LLC boosted its stake in shares of Inhibikase Therapeutics by 544.9% during the 4th quarter. Geode Capital Management LLC now owns 322,878 shares of the company's stock worth $1,049,000 after acquiring an additional 272,813 shares during the period. ADAR1 Capital Management LLC bought a new position in shares of Inhibikase Therapeutics during the 4th quarter worth approximately $16,585,000. Barclays PLC bought a new position in shares of Inhibikase Therapeutics during the 4th quarter worth approximately $273,000. Finally, Stifel Financial Corp bought a new position in shares of Inhibikase Therapeutics during the 4th quarter worth approximately $43,000. 3.81% of the stock is currently owned by institutional investors.
Inhibikase Therapeutics Stock Performance
NYSE:IKT traded up $0.01 during mid-day trading on Tuesday, hitting $2.20. 62,589 shares of the stock were exchanged, compared to its average volume of 158,557. The stock has a market capitalization of $163.55 million, a price-to-earnings ratio of -0.82 and a beta of 1.01. The firm's 50-day simple moving average is $2.10 and its 200 day simple moving average is $2.51. Inhibikase Therapeutics, Inc. has a fifty-two week low of $1.12 and a fifty-two week high of $4.20.
Analysts Set New Price Targets
Separately, HC Wainwright reiterated a "neutral" rating on shares of Inhibikase Therapeutics in a research note on Friday, March 28th.
Read Our Latest Stock Analysis on Inhibikase Therapeutics
Inhibikase Therapeutics Company Profile
(
Free Report)
Inhibikase Therapeutics, Inc, a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract.
Further Reading
Before you consider Inhibikase Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inhibikase Therapeutics wasn't on the list.
While Inhibikase Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
